Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
BMY > SEC Filings for BMY > Form 8-K on 6-Feb-2014All Recent SEC Filings

Show all filings for BRISTOL MYERS SQUIBB CO



Completion of Acquisition or Disposition of Assets, Financial Statements

Item 2.01. Completion of Acquisition or Disposition of Assets.

On February 1, 2014, Bristol-Myers Squibb (BMS) sold to AstraZeneca PLC (AstraZeneca) the diabetes business of BMS which comprised our global alliance with them, including all rights and ownership to Onglyza (saxagliptin), Forxiga (dapagliflozin), Bydureon* (exenatide extended-release for injectable suspension), Byetta* (exenatide), Symlin* (pramlintide acetate) and metreleptin. The transaction included the shares of Amylin (previously acquired by BMS in August 2012), and the resulting transfer of its manufacturing facility in West Chester, Ohio; the intellectual property related to Onglyza and Forxiga; and the future purchase of BMS's manufacturing facility located in Mount Vernon, Indiana no earlier than 18 months following the closing of the transaction. Substantially all employees dedicated to the diabetes business were transferred to AstraZeneca upon the closing of the transaction.

The closing of the transaction as it relates to the China diabetes business is subject to the satisfaction of certain conditions between BMS and its joint venture partners. The Company and AstraZeneca terminated their existing collaboration agreements in connection with the sale and entered into several new agreements, including a transitional services agreement, a supply agreement and a development agreement.

As consideration for the transaction, AstraZeneca paid $2.7 billion to BMS at closing and will make contingent regulatory and sales-based milestone payments of up to $1.4 billion (including a $600 million milestone earned in January 2014 for the United States Food and Drug Administration approval of dapagliflozin with payment due in early February 2014) and royalty payments based on net sales through 2025.

In addition, AstraZeneca will make payments of up to $225 million if and when the Mount Vernon manufacturing site and the diabetes business in China are transferred.

A copy of the press release announcing the completion of the sale is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(b) Pro Forma Financial Information

The Company's Unaudited Pro Forma Financial Information is attached hereto as Exhibit 99.2 and is incorporated herein by reference. The amounts included in the "Adjustments" column within the Company's Unaudited Pro Forma Financial Information represent the diabetes business' operating results for the respective periods using the same basis the Company utilizes.

(d) Exhibits.
99.1 Press release of Bristol-Myers Squibb Company dated February 3, 2014.

99.2 The Company's Unaudited Pro Forma Financial Information

  Add BMY to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for BMY - All Recent SEC Filings
Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.